Armin Scheffler

Real-world short-term effectiveness of erenumab after single versus multiple prior preventive treatment failures

BACKGROUND: Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide receptor, has been approved in Germany since 2018 for migraine prophylaxis. Initially, reimbursement regulations restricted its use to drug-resistant patients who had failed or were unsuitable f...